#05#

 

Revisiones-Clínica-Diagnóstico *** Reviews-Clinical-Diagnostics

 

TRASPLANTE RENAL *** RENAL TRANSPLANTATION

(Conceptos / Keywords: Renal-Kidney transplantation; Kidney donation-procurement; etc).

 

Enero / January 2001 --- Marzo / March 2004

 

La biblioteca del conocimiento biomédico© es un servicio GRATUITO. Toda la información ha sido obtenida de fuentes públicas, de portales de internet que no requieren registro alguno para su uso, que no requieren estar de acuerdo con sus Términos de uso, que son de libre acceso a todo el mundo, y son a su vez gratuitos. La biblioteca (revisiones, guías, protocolos, medicina basada en la evidencia, etc...) se recopila en base a una patente que permite a Effiloop la catalogación de los artículos por campos de interés así como por el orden de su importancia (se proveen las primeras 200 revisiones). Toda la informacion se ampara en las leyes de libre pensamiento-expresión, y de uso justo. Este documento sólo contiene artículos escritos en Castellano y/o Inglés.

 

The biomedical library© is a FREE service. All the information has been obtained from public sources, from web sites that do not require registration for their use, that do not require an agreement with their Terms of use, that provide free access for all, and are free of charge. The library (reviews, guides, protocols, medicine based medicine, etc) is arranged according to a patent that warrants Effiloop to catalogue the articles by fields of interest as well as to sort articles by true relevance (the first 200 reviews are provided). All the information is provided according to the freedom of speech and fair use laws. Only articles written in Spanish and/or English are included.

Enlace / Link

 

[1]

TÍTULO / TITLE:  - Diagnosis and therapy of coronary artery disease in renal failure, end-stage renal disease, and renal transplant populations.

REVISTA / JOURNAL:  - Am J Med Sci 2003 Apr;325(4):214-27.

AUTORES / AUTHORS:  - Logar CM; Herzog CA; Beddhu S

INSTITUCIÓN / INSTITUTION:  - Renal Section, Salt Lake VA Healthcare System, Department of Medicine, University of Utah School of Medicine, Salt Lake City, USA.

RESUMEN / SUMMARY:  - Even though cardiovascular disease is the leading cause of death in patients with CRF and end-stage renal disease (ESRD), ill-conceived notions have led to therapeutic nihilism as the predominant strategy in the management of cardiovascular disease in these populations. The recent data clearly support the application of proven interventions in the general population, such as angiotensin-converting enzyme inhibitors and statins to patients with CRF and ESRD. The advances in coronary stents and intracoronary irradiation have decreased the restenosis rates in renal failure patients. Coronary artery bypass with internal mammary graft might be the procedure of choice for coronary revascularization in these patients. The role of screening for asymptomatic coronary disease is established as a pretransplant procedure, but it is unclear whether this will be applicable to all patients with ESRD. Future studies need to focus on unraveling the mechanisms by which uremia leads to increased cardiovascular events to design optimal therapies targeted toward these mechanisms and improve cardiovascular outcomes.  N. Ref:: 125

 

----------------------------------------------------

[2]

TÍTULO / TITLE:  - 4D imaging to assay complex dynamics in live specimens.

REVISTA / JOURNAL:  - Nat Cell Biol 2003 Sep;Suppl:S14-9.

AUTORES / AUTHORS:  - Gerlich D; Ellenberg J

INSTITUCIÓN / INSTITUTION:  - Gene Expression and Cell Biology/Biophysics Programmes, European Molecular Biology Laboratory, Heidelberg, Germany.

RESUMEN / SUMMARY:  - A full understanding of cellular dynamics is often difficult to obtain from time-lapse microscopy of single optical sections. New microscopes and image-processing software are now making it possible to rapidly record three-dimensional images over time. This four-dimensional imaging allows precise quantitative analysis and enhances visual exploration of data by allowing cellular structures to be interactively displayed from many angles. It has become a key tool for understanding the complex organization of biological processes in live specimens.  N. Ref:: 55

 

----------------------------------------------------

[3]

TÍTULO / TITLE:  - Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings.

REVISTA / JOURNAL:  - J Am Soc Nephrol. Acceso gratuito al texto completo a partir de 1 año de la fecha de publicación.

      ●● Enlace a la Editora de la Revista http://www.jasn.org/ 

      ●● Cita: Journal of the American Society of Nephrology: <> 2003 Mar;14(3):755-66.

AUTORES / AUTHORS:  - Gotti E; Perico N; Perna A; Gaspari F; Cattaneo D; Caruso R; Ferrari S; Stucchi N; Marchetti G; Abbate M; Remuzzi G

INSTITUCIÓN / INSTITUTION:  - Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Italy.

RESUMEN / SUMMARY:  - How to combine antirejection drugs and which is the optimal dose of steroids and calcineurin inhibitors beyond the first year after kidney transplantation to maintain adequate immunosuppression without major side effects are far from clear. Kidney transplant patients on steroid, cyclosporine (CsA), and azathioprine were randomized to per-protocol biopsy (n = 30) or no-biopsy (n = 29) 1 to 2 yr posttransplant. Steroid or CsA were discontinued or reduced on the basis of biopsy to establish effects on drug-related complications, acute rejection, and graft function over 3 yr of follow-up. Serum creatinine, GFR (plasma clearance of iohexol), RPF (renal clearance of p-aminohippurate), CsA pharmacokinetics, and adverse events were monitored yearly. At the end, patients underwent a second biopsy. Per-protocol biopsy histology revealed no lesions (n = 5, steroid withdrawal), CsA nephropathy (n = 13, CsA discontinuation/reduction), or chronic rejection (n = 12, standard therapy). Reducing the drug regimen led to overall fewer side effects related to immunosuppression as compared with standard therapy or no-biopsy. Steroids were safely stopped with no acute rejection or graft loss. Complete CsA discontinuation was associated with acute rejection in the first four patients. Lowering CsA to low target CsA trough (30 to 70 ng/ml) never led to acute rejection or major renal function deterioration. Biopsy patients on conventional regimen had no acute rejection, one graft loss, no significant change in GFR, and significant RPF decline. No-biopsy controls: no acute rejection, one graft loss, significant decline of GFR and RPF. By serial biopsy analysis, severe lesions did not develop in patients with steroid discontinuation in contrast to patients on standard therapy over follow-up. CsA reduction did not adversely affect histology. Per-protocol biopsy more than 1 yr after kidney transplantation is a safe procedure to guide change of drug regimen and to lower the risk of major side effects.

 

----------------------------------------------------

[4]

TÍTULO / TITLE:  - Regulatory T cells in kidney transplant recipients: active players but to what extent?

REVISTA / JOURNAL:  - J Am Soc Nephrol. Acceso gratuito al texto completo a partir de 1 año de la fecha de publicación.

      ●● Enlace a la Editora de la Revista http://www.jasn.org/ 

      ●● Cita: Journal of the American Society of Nephrology: <> 2003 Jun;14(6):1706-8.

AUTORES / AUTHORS:  - Zhai Y; Kupiec-Weglinski JW  N. Ref:: 20

 

----------------------------------------------------

[5]

TÍTULO / TITLE:  - Protocol core needle biopsy and histologic Chronic Allograft Damage Index (CADI) as surrogate end point for long-term graft survival in multicenter studies.

REVISTA / JOURNAL:  - J Am Soc Nephrol. Acceso gratuito al texto completo a partir de 1 año de la fecha de publicación.

      ●● Enlace a la Editora de la Revista http://www.jasn.org/ 

      ●● Cita: Journal of the American Society of Nephrology: <> 2003 Mar;14(3):773-9.

AUTORES / AUTHORS:  - Yilmaz S; Tomlanovich S; Mathew T; Taskinen E; Paavonen T; Navarro M; Ramos E; Hooftman L; Hayry P

INSTITUCIÓN / INSTITUTION:  - Data Analysis Center, Division of Transplantation, Department of Surgery, University of Calgary, Alberta, Canada.

RESUMEN / SUMMARY:  - This study is an investigation of whether a protocol biopsy may be used as surrogate to late graft survival in multicenter renal transplantation trials. During two mycophenolate mofetil trials, 621 representative protocol biopsies were obtained at baseline, 1 yr, and 3 yr. The samples were coded and evaluated blindly by two pathologists, and Chronic Allograft Damage Index (CADI) score was constructed. At 1 yr, only 20% of patients had elevated (>l.5 mg/100 ml) serum creatinine, whereas 60% of the biopsies demonstrated an elevated (>2.0) CADI score. The mean CADI score at baseline, 1.3 +/- 1.1, increased to 3.3 +/- 1.8 at 1 yr and to 4.1 +/- 2.2 at 3 yr. The patients at 1 yr were divided into three groups, those with CADI <2, between 2 and 3.9, and >4.0, the first two groups having normal (1.4 +/- 0.3 and 1.5 +/- 0.6 mg/dl) and the third group pathologic (1.9 +/- 0.8 mg/dl) serum creatinine. At 3 yr, there were no lost grafts in the low CADI group, six lost grafts (4.6%) in the in the elevated CADI group, and 17 lost grafts (16.7%) in the high CADI group (P < 0.001). One-year histologic CADI score predicts graft survival even when the graft function is still normal. This observation makes it possible to use CADI as a surrogate end point in prevention trials and to identify the patients at risk for intervention trials.

 

----------------------------------------------------

[6]

TÍTULO / TITLE:  - Postmenopausal tubo-ovarian abscess due to Pseudomonas aeruginosa in a renal transplant patient: a case report and review of the literature.

REVISTA / JOURNAL:  - Transplantation 2001 Oct 15;72(7):1241-4.

AUTORES / AUTHORS:  - El Khoury J; Stikkelbroeck MM; Goodman A; Rubin RH; Cosimi AB; Fishman JA

INSTITUCIÓN / INSTITUTION:  - Infectious Disease Division, GRJ 504, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

RESUMEN / SUMMARY:  - BACKGROUND: Pseudomonas aeruginosa is an uncommon cause of infection in the female genital tract. We report a case of postmenopausal tubo-ovarian abscess (TOA) due to P. aeruginosa in a renal transplant recipient. The presentation included mild abdominal symptoms with rapid progression of peritonitis and surgical abscess drainage. This is the first such case in an organ transplant recipient described in the English literature. METHODS AND RESULTS: Published reports of 1040 cases of TOA were reviewed. The most common features were a history of sexually transmitted disease or pelvic inflammatory disease, and symptoms including abdominal pain and fever. Escherichia coli, Bacteroides spp., and Klebsiella pneumoniae were the most frequently encountered pathogens. Neisseria gonorrhoeae and Chlamydia trachomatis, which are frequently isolated from cervical cultures, are uncommonly isolated from tubo-ovarian abscesses. Forty percent of patients were treated with antibiotics alone, 18.8% with abdominal surgery, and 32% with surgery and antimicrobial therapy. CONCLUSION: This report illustrates the muted presentation and atypical microbiology of gynecologic infection in an organ transplant recipient.  N. Ref:: 59

 

----------------------------------------------------

[7]

- Castellano -

TÍTULO / TITLE:Polimorfismo del receptor de la vitamina D y enfermedad osea postrasplante renal. Polymorphism of the vitamin D receptor and bone disease after renal transplantation.

REVISTA / JOURNAL:  - Nefrologia. Acceso gratuito al texto completo.

      ●● Enlace a la Editora de la Revista http://www.aulamedica.es/nefrologia/ 

      ●● Cita: Nefrologia: <> 2001;21 Suppl 1:56-60.

AUTORES / AUTHORS:  - Torres A; Barrios Y; Salido E

INSTITUCIÓN / INSTITUTION:  - Servicio de Nefrologia y, Hospital Universitario de Canarias, Instituto Reina Sofia de Investigacion Nefrologica, Tenerife, España. atorres@ull.es  N. Ref:: 29

 

----------------------------------------------------

[8]

TÍTULO / TITLE:  - Management of the waiting list for cadaveric kidney transplants: report of a survey and recommendations by the Clinical Practice Guidelines Committee of the American Society of Transplantation.

REVISTA / JOURNAL:  - J Am Soc Nephrol. Acceso gratuito al texto completo a partir de 1 año de la fecha de publicación.

      ●● Enlace a la Editora de la Revista http://www.jasn.org/ 

      ●● Cita: Journal of the American Society of Nephrology: <> 2002 Feb;13(2):528-35.

AUTORES / AUTHORS:  - Danovitch GM; Hariharan S; Pirsch JD; Rush D; Roth D; Ramos E; Starling RC; Cangro C; Weir MR

INSTITUCIÓN / INSTITUTION:  - Division of Nephrology, University of California, Los Angeles, School of Medicine, Los Angeles, California 90025, USA. gdanovitch@mednet.ucla.edu

RESUMEN / SUMMARY:  - The Clinical Practice Guidelines Committee of the American Society of Transplantation developed a survey to review the policies of kidney transplant programs in the United States with respect to the management of the steadily expanding waiting list for cadaveric kidneys. The survey was sent to 287 centers, and 192 (67%) responded. The survey indicated that regular follow-up monitoring, most frequently on an annual basis, is required by the majority (71%) of programs. Patients considered to be at high risk and candidates for combined kidney-pancreas transplantation may be monitored more frequently. Annual screening for coronary artery disease is typically required for asymptomatic patients considered to be at high risk for covert disease. Noninvasive techniques are typically used, and a designated cardiologist is usually available to the transplant program. The dialysis nephrologist or the potential transplant recipient is expected to inform the transplant program of intercurrent events that may affect transplant candidacy. Standard health maintenance screening is required, together with the routine updating of serologic and other blood tests that may be relevant to the posttransplant course. Smaller transplant programs (<100 patients on the waiting list) are more likely to maintain closer contact with the wait-listed patients and to attempt to influence their treatment during dialysis and are less likely to cancel transplants because of unanticipated pretransplant medical problems. The work load necessitated by the follow-up monitoring of wait-listed patients was assessed and, in the absence of specific evidence-based information, a series of recommendations were developed to reflect current standards of practice and to suggest future research initiatives.

 

----------------------------------------------------

[9]

TÍTULO / TITLE:  - Nonmelanoma skin cancer in organ transplant patients.

REVISTA / JOURNAL:  - Transplantation 2003 Feb 15;75(3):253-7.

      ●● Enlace al texto completo (gratuito o de pago) 1097/01.TP.0000044135.92850.75

AUTORES / AUTHORS:  - Jemec GB; Holm EA

INSTITUCIÓN / INSTITUTION:  - Division of Dermatology, Department of Medicine, Roskilde Hospital, 4000 Roskilde, Denmark. ccc2845@vip.cybercity.dk

RESUMEN / SUMMARY:  - Nonmelanoma skin cancer (NMSC) is more frequent in immunocompromised patients, for example, patients with organ transplants. A number of studies have been published from different countries that present a similar picture of tumors in transplant patients. In addition, the behavior of these tumors is often more aggressive in this group of high-risk patients. The multitude of NMSC and precancerous lesions presents a clinical diagnostic and therapeutic challenge to the managing dermatologists. Technology is being developed to cope with the clinical diagnosis and medical adjunct treatment to broaden the therapeutic options. It is suggested that the optimal use of these new developments occurs if patients are seen in specialized clinics aimed at providing preventive measures, diagnosis, and treatment.  N. Ref:: 50

 

----------------------------------------------------

[10]

TÍTULO / TITLE:  - Ambulatory blood pressure measurement in kidney transplantation: an overview.

REVISTA / JOURNAL:  - Transplantation 2003 Dec 15;76(11):1643-4.

      ●● Enlace al texto completo (gratuito o de pago) 1097/01.TP.0000091289.03300.1A

AUTORES / AUTHORS:  - Tomson CR

INSTITUCIÓN / INSTITUTION:  - Department of Renal Medicine, Southmead Hospital, Bristol, UK. charlie.tomson@north-bristol.swest.nhs.uk

RESUMEN / SUMMARY:  - Adequate control of hypertension is among the most important aims of medical management of the kidney transplant recipient, with the aim of reducing the risk of premature cardiovascular disease and preserving graft function. Antihypertensive therapy should be adjusted according to the best available estimates of usual resting blood pressure. If clinic measurements are used, care should be taken to ensure that these measurements are taken under optimal conditions. Home blood pressure monitoring is a useful adjunct in many patients. Ambulatory blood pressure monitoring gives valuable additional data; mean ambulatory blood pressure correlates better with markers of target organ damage such as left ventricular hypertrophy. However, current treatment thresholds and targets are based on clinic measurements. Ambulatory blood pressure monitoring is certainly a useful adjunct to clinic and home blood pressure measurement, but its role in routine clinical practice in the transplant clinic remains to be defined.  N. Ref:: 11

 

----------------------------------------------------

[11]

TÍTULO / TITLE:  - Updated protocol for the examination of specimens from patients with carcinoma of the urinary bladder, ureter, and renal pelvis.

REVISTA / JOURNAL:  - Arch Pathol Lab Med. Acceso gratuito al texto completo.

      ●● Enlace a la Editora de la Revista http://arpa.allenpress.com/ 

      ●● Cita: Archives of Pathology & Laboratory Medicine: <> 2003 Oct;127(10):1263-79.

AUTORES / AUTHORS:  - Amin MB; Srigley JR; Grignon DJ; Reuter VE; Humphrey PA; Cohen MB; Hammond ME

INSTITUCIÓN / INSTITUTION:  - Department of Pathology, Emory University Hospital, Atlanta, Ga, USA.

 

----------------------------------------------------

[12]

TÍTULO / TITLE:  - Renal transplantation in HBsAg+ patients: is lamivudine your “final answer”?

REVISTA / JOURNAL:  - J Clin Gastroenterol 2003 Jul;37(1):9-11.

AUTORES / AUTHORS:  - Fontana RJ  N. Ref:: 30

 

----------------------------------------------------

[13]

TÍTULO / TITLE:  - Infectious disease prophylaxis in renal transplant patients: a survey of US transplant centers.

REVISTA / JOURNAL:  - Clin Transplant 2002 Feb;16(1):1-8.

AUTORES / AUTHORS:  - Batiuk TD; Bodziak KA; Goldman M

INSTITUCIÓN / INSTITUTION:  - Department of Medicine, Indiana University Medical Center, Indianapolis, USA. tbatiuk@iupui.edu

RESUMEN / SUMMARY:  - Definitive approaches to most infectious diseases following renal transplantation have not been established, leading to different approaches at different transplant centers. To study the extent of these differences, we conducted a survey of the practices surrounding specific infectious diseases at US renal transplant centers. A survey containing 103 questions covering viral, bacterial, mycobacterial and protozoal infections was developed. Surveys were sent to program directors at all U.S. renal transplant centers. Responses were received from 147 of 245 (60%) transplant centers and were proportionately represented all centers with respect to program size and geographical location. Pre-transplant donor and recipient screening for hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) and cytomegalovirus (CMV) is uniform, but great discrepancy exists in the testing for other agents. HCV seropositive donors are used in 49% of centers. HIV seropositivity remains a contraindication to transplantation, although 13% of centers indicated they have experience with such patients. Post-transplant, there is wide variety in approach to CMV and Pneumocystis carinii (PCP) prophylaxis. Similarly divergent practices affect post-transplant vaccinations, with 54% of centers routinely vaccinating all patients according to customary guidelines in non-transplant populations. In contrast, 22% of centers indicated they do not recommend vaccination in any patients. We believe an appreciation of the differences in approaches to post-transplant infectious complications may encourage individual centers to analyse the results of their own practices. Such analysis may assist in the design of studies to answer widespread and important questions regarding the care of patients following renal transplantation.  N. Ref:: 38

 

----------------------------------------------------

[14]

TÍTULO / TITLE:  - Current treatment strategies in ANCA-positive renal vasculitis-lessons from European randomized trials.

REVISTA / JOURNAL:  - Nephrol Dial Transplant. Acceso gratuito al texto completo a partir de los 2 años de la fecha de publicación.

      ●● Enlace a la Editora de la Revista http://ndt.oupjournals.org/ 

      ●● Cita: Nephrology Dialysis Transplantation: <> 2003 Jul;18 Suppl 5:v2-4.

AUTORES / AUTHORS:  - Tesar V; Rihova Z; Jancova E; Rysava R; Merta M

INSTITUCIÓN / INSTITUTION:  - First Medical Department, First Medical Faculty, Charles University, Prague, Czech Republic. tesar@beba.cesnet.cz

RESUMEN / SUMMARY:  - Antineutrophil cytoplasmic antibody (ANCA)-positive renal vasculitis is the most common cause of rapidly progressive (crescentic) glomerulonephritis. Its life-threatening natural course may be modified substantially by current treatment modalities. The European Vasculitis Study Group (EUVAS) developed a subclassification of ANCA-positive vasculitides based on the disease severity at presentation, and have organized (so far) two waves of clinical trials. The first wave of randomized clinical trials had the aim of optimizing the existing therapeutic regimens; the second wave concentrated on testing some newer therapeutic approaches. Here, the design and available results of the first wave and the design of some second wave trials are reviewed briefly. The potential of the new targeted approaches (e.g. anti-tumour necrosis factor therapy) is also briefly mentioned.  N. Ref:: 9

 

----------------------------------------------------

[15]

TÍTULO / TITLE:  - How should the immunosuppressive regimen be managed in patients with established chronic allograft failure?

REVISTA / JOURNAL:  - Kidney Int Suppl 2002 May;(80):68-72.

AUTORES / AUTHORS:  - Danovitch GM

INSTITUCIÓN / INSTITUTION:  - Division of Nephrology, UCLA School of Medicine, USA. gdanovitch@mednet.ucla.edu  N. Ref:: 25

 

----------------------------------------------------

[16]

TÍTULO / TITLE:  - Costs and consequences of cytomegalovirus disease.

REVISTA / JOURNAL:  - Am J Health Syst Pharm 2003 Dec 1;60(23 Suppl 8):S5-8.

AUTORES / AUTHORS:  - Schnitzler MA

INSTITUCIÓN / INSTITUTION:  - Washington University, 4547 Clayton Avenue, Box 8084, St. Louis, MO 63110, USA. schnitz@wueconc.edu

RESUMEN / SUMMARY:  - The impact of prophylactic oral ganciclovir therapy on the incidence of cytomegalovirus (CMV) disease, patient and graft survival, and costs in patients receiving kidney and liver transplants is described. CMV disease is a common cause of morbidity and mortality in solid organ transplant recipients unless prophylactic drug therapy is used. Prophylactic oral ganciclovir therapy reduces the incidence of CMV disease in kidney and liver transplant recipients. It is more effective for recipients who are seronegative before the transplant and receive organs from seronegative (D-/R-) donors than in seronegative recipients of organs from seropositive (D+/R-) donors. CMV disease remains a problem in the latter. CMV disease increases the risk of graft failure, which decreases the likelihood of patient survival. The extent of matching of the DR subregion of the human leukocyte antigen complex in the donor and recipient may affect graft survival in patients with CMV disease. Graft failure is costly and should be considered in economic analyses of CMV prophylaxis regimens because of the potential impact of prophylaxis on CMV disease. The use of oral ganciclovir for CMV prophylaxis has reduced the incidence of CMV disease in kidney and liver transplant recipients.  N. Ref:: 10

 

----------------------------------------------------

[17]

TÍTULO / TITLE:  - Protocol for the examination of specimens from patients with Wilms tumor (nephroblastoma) or other renal tumors of childhood.

REVISTA / JOURNAL:  - Arch Pathol Lab Med. Acceso gratuito al texto completo.

      ●● Enlace a la Editora de la Revista http://arpa.allenpress.com/ 

      ●● Cita: Archives of Pathology & Laboratory Medicine: <> 2003 Oct;127(10):1280-9.

AUTORES / AUTHORS:  - Qualman SJ; Bowen J; Amin MB; Srigley JR; Grundy PE; Perlman EJ

INSTITUCIÓN / INSTITUTION:  - Department of Laboratory Medicine, Children’s Hospital, Columbus, Ohio 43205, USA. qualmans@pediatrics.ohio-state.edu

 

----------------------------------------------------

[18]

TÍTULO / TITLE:  - Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates.

REVISTA / JOURNAL:  - Transplantation 2003 Sep 27;76(6):969-73.

      ●● Enlace al texto completo (gratuito o de pago) 1097/01.TP.0000082542.99416.11

AUTORES / AUTHORS:  - Furness PN; Philpott CM; Chorbadjian MT; Nicholson ML; Bosmans JL; Corthouts BL; Bogers JJ; Schwarz A; Gwinner W; Haller H; Mengel M; Seron D; Moreso F; Canas C

INSTITUCIÓN / INSTITUTION:  - Clinical Sciences Laboratories, Leicester General Hospital, Leicester, United Kingdom.

RESUMEN / SUMMARY:  - BACKGROUND: Clinical trials in renal transplantation must use surrogate markers of long-term graft survival if conclusions are to be drawn at acceptable speed and cost. Morphologic changes in transplant biopsies provide the earliest available evidence of damage, and “protocol” biopsies from stable grafts can be used to reduce the number of patients needed in clinical trials. This approach has been inhibited by concerns over safety, but the risk of biopsy of a stable kidney, with no active inflammation or acute functional impairment, has never been formally estimated. METHODS: In accordance with a predefined set of questions, a retrospective audit of a sequential series of protocol biopsies was performed in four major transplant centers. RESULTS: A total of 2,127 biopsy events were assessed for major complications, and 1,486 were assessed for minor ones. There were no deaths. One graft was lost, under circumstances indicating that the loss should have been prevented. Three episodes of hemorrhage required direct intervention. Three further patients required transfusion. There were two episodes of peritonitis, but one was arguably an unrelated event. All serious complications presented within 4 hr of biopsy. CONCLUSIONS: The incidence of clinically significant complications after protocol biopsy of a stable renal transplant is low. Direct benefits to the patients concerned (irrespective of the benefit that may accrue in clinical trials) were not formally assessed but seem likely to outweigh the risk of the procedure. We believe that it is ethically justifiable to ask renal transplant recipients to undergo protocol biopsies in clinical trials and routine care.

 

----------------------------------------------------

[19]

TÍTULO / TITLE:  - Steroid-resistant kidney transplant rejection: diagnosis and treatment.

REVISTA / JOURNAL:  - J Am Soc Nephrol. Acceso gratuito al texto completo a partir de 1 año de la fecha de publicación.

      ●● Enlace a la Editora de la Revista http://www.jasn.org/ 

      ●● Cita: Journal of the American Society of Nephrology: <> 2001 Feb;12 Suppl 17:S48-52.

AUTORES / AUTHORS:  - Bock HA

INSTITUCIÓN / INSTITUTION:  - Division of Nephrology, Kantonsspital, Aarau, Switzerland. bock@ksa.ch

RESUMEN / SUMMARY:  - Decreases in transplant function may be attributable to a variety of conditions, including prerenal and postrenal failure, cyclosporin A (CsA) toxicity, polyoma nephritis, recurrent glomerulonephritis, and rejection. The diagnosis of rejection should therefore be made on the basis of a transplant biopsy of adequate size, before the initiation of any therapy. Pulse steroid treatment (three to five 0.25- to 1.0-g pulses of methylprednisolone, administered intravenously) is the usual first-line therapy and has a 60 to 70% success rate, although orally administered prednisone (0.25 g) may be just as efficacious. Even if reverted, any rejection should trigger an at least temporary increase in basal immunosuppression, consisting of an increase in CsA or tacrolimus target levels, the addition of steroids or an increase in their dosage, the addition of mycophenolate mofetil, or a switch from CsA to tacrolimus. The addition of rapamycin or its RAD derivative may fulfill the same purpose. Steroid resistance should not be assumed before the fifth day of pulse steroid treatment, although histologic features of vascular rejection may indicate the need for more aggressive treatment earlier. Steroid-resistant rejection is traditionally treated with poly- or monoclonal antilymphocytic antibodies, with success rates of 60 to 70%. Their potential benefit must be carefully balanced against the risks of infection and lymphoma. More recently, mycophenolate mofetil has been successfully used to treat steroid-resistant rejection, but only of the interstitial (cellular) type. Switching from CsA to tacrolimus for treating recurrent or antibody-resistant rejection is successful in approximately 60% of cases. Plasmapheresis and intravenously administered Ig have been used in some desperate cases, with surprising success. Because none of the available drugs has a significantly better profile of therapeutic versus adverse effects, the possible benefits of continued rejection therapy must be continuously balanced with the potential for serious, sometimes fatal, side effects.  N. Ref:: 35

 

----------------------------------------------------

[20]

TÍTULO / TITLE:  - Vitamin D as immunomodulatory therapy for kidney transplantation.

REVISTA / JOURNAL:  - Transplantation 2002 Oct 27;74(8):1204-6.

      ●● Enlace al texto completo (gratuito o de pago) 1097/01.TP.0000031949.70610.BB

AUTORES / AUTHORS:  - Becker BN; Hullett DA; O’Herrin JK; Malin G; Sollinger HW; DeLuca H

INSTITUCIÓN / INSTITUTION:  - Department of Medicine, B-3063 UW Nephrology, University of Wisconsin, 2500 Overlook Terrace, Madison, WI 53705, USA. bnb@medicine.wisc.edu

RESUMEN / SUMMARY:  - Vitamin D (1alpha,25-dihydroxyvitamin D(3) [1alpha,25-(OH)(2)D(3)]) has been studied in the past for its immunosuppressive properties, and, in that context, it may also have potential utility as an immunomodulatory agent for transplantation. A number of studies have demonstrated that 1alpha,25-(OH)(2)D(3) or its analogs regulate immune cell proliferation, differentiation, and responsiveness. A burgeoning number of studies have also explored using 1alpha,25-(OH)(2)D(3) and its analogs directly as therapy in animal models of kidney transplantation with success in prolonging allograft function and preventing acute rejection. Some of these in vivo effects may well be caused by alterations in immune cell function, but it is also possible that exogenous 1alpha,25-(OH)(2)D(3) and its analogs are altering the intragraft milieu as well, specifically through changes in the TGF-beta signaling cascade. Such provocative data and the availability of newer 1alpha,25-(OH)(2)D(3) analogs that may limit side effects (e.g. hypercalcemia) have created interest in examining this secosteroid clinically in kidney transplantation.  N. Ref:: 34

 

----------------------------------------------------

[21]

TÍTULO / TITLE:  - Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients.

REVISTA / JOURNAL:  - Clin Biochem 2001 Feb;34(1):17-22.

AUTORES / AUTHORS:  - Shaw LM; Korecka M; DeNofrio D; Brayman KL

INSTITUCIÓN / INSTITUTION:  - Departments of Pathology & Laboratory Medicine and Surgery, University of Pennsylvania Medical Center, Philadelphia, PA, USA. shawlmj@mail.med.upenn.edu

RESUMEN / SUMMARY:  - Mycophenolate mofetil is widely used in combination with either cyclosporine or tacrolimus for rejection prophylaxis in renal and heart transplant patients. Although not monitored routinely nearly to the degree that other agents such as cyclosporine or tacrolimus, there is an expanding body of experimental evidence for the utility of monitoring mycophenolic acid, the primary active metabolite of mycophenolate mofetil, plasma concentration as an index of risk for the development of acute rejection. The following are important experimentally-based reasons for recommending the incorporation of target therapeutic concentration monitoring of mycophenolic acid: (1) the MPA dose-interval area-under-the-concentration-time curve, and less precisely, MPA predose concentrations predict the risk for development of acute rejection; (2) the strong correlation between mycophenolic acid plasma concentrations and expression of important cell surface activation antigens, whole blood pharmacodynamic assays of lymphocyte proliferation and median graft rejection scores in a heart transplant animal model; (3) the greater than 10-fold interindividual variation of MPA area under the concentration time curve values in heart and renal transplant patients receiving a fixed dose of the parent drug; (4) drug-drug interactions involving other immunosuppressives are such that when switching from one to another (eg, from cyclosporine to tacrolimus or vice-versa) substantial changes in MPA concentrations can occur in patients receiving a fixed dose of the parent drug; (5) significant effects of liver and kidney diseases on the steady-state total and free mycophenolic acid area under the concentration time curve values; (6) the need to closely monitor mycophenolic acid when a major change in immunosuppression is planned such as steroid withdrawal. Current investigations are focused on determination of the most optimal sampling time and for mycophenolic acid target therapeutic concentration monitoring. Further investigations are needed to evaluate the pharmacologic activity of the newly described acyl glucuronide metabolite of mycophenolic acid which has been shown to inhibit, in vitro, inosine monophosphate dehydrogenase.  N. Ref:: 37

 

----------------------------------------------------

[22]

TÍTULO / TITLE:  - Capillary C4d deposition as a marker of humoral immunity in renal allograft rejection.

REVISTA / JOURNAL:  - J Am Soc Nephrol. Acceso gratuito al texto completo a partir de 1 año de la fecha de publicación.

      ●● Enlace a la Editora de la Revista http://www.jasn.org/ 

      ●● Cita: Journal of the American Society of Nephrology: <> 2002 Sep;13(9):2420-3.

AUTORES / AUTHORS:  - Watschinger B; Pascual M  N. Ref:: 38

 

----------------------------------------------------

[23]

TÍTULO / TITLE:  - European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.2.1 Differential diagnosis of chronic graft dysfunction.

REVISTA / JOURNAL:  - Nephrol Dial Transplant. Acceso gratuito al texto completo a partir de los 2 años de la fecha de publicación.

      ●● Enlace a la Editora de la Revista http://ndt.oupjournals.org/ 

      ●● Cita: Nephrology Dialysis Transplantation: <> 2002;17 Suppl 4:4-8.

RESUMEN / SUMMARY:  - GUIDELINES: A. Any significant deterioration in graft function should be investigated using the appropriate diagnostic tools and, if possible, therapeutic interventions should be initiated. The usual causes of a decline in glomerular filtration rate after the first year include transplant-specific causes such as chronic allograft nephropathy, acute rejection episodes, chronic calcineurin inhibitor nephrotoxicity, transplant renal artery stenosis and ureteric obstruction, as well as immunodeficiency-related causes and non-transplant-related causes, such as recurrent or de novo renal diseases and bacterial infections. B. Any new onset and persistent proteinuria of >0.5 g/24 h should be investigated and therapeutic interventions should be initiated. The usual causes include chronic allograft nephropathy and transplant glomerulopathy, and recurrent or de novo glomerulonephritis.

 

----------------------------------------------------

[24]

- Castellano -

TÍTULO / TITLE:Reporte preliminar. Utilidad de la angiotomografia renal en el protocolo del donador renal. Preliminary report. Usefulness of computed tomographic angiography in the protocol of a kidney donor.

REVISTA / JOURNAL:  - Cir Cir. Acceso gratuito al texto completo.

      ●● Enlace a la Editora de la Revista http://www.medigraphic.com/ 

      ●● Cita: Cirugia y Cirujanos: <> 2003 Sep-Oct;71(5):379-82.

AUTORES / AUTHORS:  - Ramirez-Bollas J; Hernandez-Dominguez M; Arenas-Osuna J; Romero-Huesca A; Albores-Zuniga O

INSTITUCIÓN / INSTITUTION:  - Cirujano General, Hospital de Especialidades del Centro Medico Nacional “La Raza,” IMSS, Mexico D.F., Mexico. juliobollas@yahoo.com.mx

RESUMEN / SUMMARY:  - OBJECTIVE: To determine clinical correlation of reports of computed tomographic angiography renal (CT-AR) and surgical findings of the kidney donor patient. MATERIAL AND METHODS: Patients were submitted nephrectomy in the related live donor renal transplant program between January and December 2002 as paut of life to which he is made as he CT-AR study protocol. Statistical analysis was carried out by descriptive statistics. RESULTS: Anatomical characteristics of 35 kidneys of the same number of live donors (AD) submitted CT-AR were evaluated and comparison with report of surgical technique was made. Incidence of accessory renal arteries was 23%. As reported by CT-AR, the were 39 renal arteries (91%) compared with 43 arteries found during surgery. CT-AR identified four supernumerary renal arteries (50%) of eight identified during surgical technique; 36 hiliar arteries (90%) and three polar arteries were identified by CT-AR (100%). Only one a case report of early bifurcation of renal artery (20%) by CT-AR was recorded. Anatomical characteristics of veins were described in their totality. CT-AR is a useful instrument to identify alterations in anatomical structure of the renal vasculature, with results similar to other studies for description of renal arteries and veins. We propose ATR as the initial study for evaluation of the renal architecture of the live kidney (LKD).

 

----------------------------------------------------

[25]

TÍTULO / TITLE:  - The impact of cytomegalovirus infections and acute rejection episodes on the development of vascular changes in 6-month protocol biopsy specimens of cadaveric kidney allograft recipients.

REVISTA / JOURNAL:  - Transplantation 2003 Jun 15;75(11):1858-64.

      ●● Enlace al texto completo (gratuito o de pago) 1097/01.TP.0000064709.20841.E1

AUTORES / AUTHORS:  - Helantera I; Koskinen P; Tornroth T; Loginov R; Gronhagen-Riska C; Lautenschlager I

INSTITUCIÓN / INSTITUTION:  - Department of Virology, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.

RESUMEN / SUMMARY:  - BACKGROUND: The role of cytomegalovirus (CMV) in chronic kidney allograft rejection remains controversial. The purpose of this study was to examine the impact of CMV infection on histopathologic changes in 6-month protocol biopsy specimens of kidney allografts. METHODS: Altogether, 52 renal allograft recipients were studied. CMV infection was diagnosed by CMV antigenemia test, viral cultures from blood and urine, or both. CMV was demonstrated in the biopsy specimens by antigen detection and hybridization in situ. Acute rejections were diagnosed by biopsy histology, and biopsy specimens were graded according to the Banff ‘97 classification. RESULTS: CMV infection was diagnosed in 41 patients. The 11 patients in whom CMV infection was not detected were used as controls. Acute rejection was diagnosed in 22 of 41 CMV patients and in 6 of 11 control patients. CMV was demonstrated in the biopsy specimens of 19 of 41 CMV patients. CMV was not associated with increased glomerular, tubular, or interstitial changes. However, the arteriosclerotic changes in small arterioles were significantly increased in the subgroup of patients where CMV was demonstrated in the graft as compared with controls (P<0.01). Analysis of the impact of acute rejection on arteriolar thickening showed that only a positive history of both acute rejection and CMV found in the graft was associated with significantly increased vascular changes compared with CMV-free recipients (P<0.05). CONCLUSIONS: Neither CMV nor acute rejection alone was associated with increased vascular or other histopathologic changes in 6-month protocol biopsy specimens of kidney allografts, but a previous history of both acute rejection and the presence of CMV in the graft was associated with increased vascular changes.

 

----------------------------------------------------

[26]

TÍTULO / TITLE:  - Transplant capillaropathy and transplant glomerulopathy: ultrastructural markers of chronic renal allograft rejection.

REVISTA / JOURNAL:  - Nephrol Dial Transplant. Acceso gratuito al texto completo a partir de los 2 años de la fecha de publicación.

      ●● Enlace a la Editora de la Revista http://ndt.oupjournals.org/ 

      ●● Cita: Nephrology Dialysis Transplantation: <> 2003 Apr;18(4):655-60.

AUTORES / AUTHORS:  - Ivanyi B

INSTITUCIÓN / INSTITUTION:  - Department of Pathology, University of Szeged, Szeged, Hungary. ivanyi@patho.szote.u-szeged.hu  N. Ref:: 21

 

----------------------------------------------------

[27]

TÍTULO / TITLE:  - Adenovirus pyelonephritis in a pediatric renal transplant patient.

REVISTA / JOURNAL:  - Pediatr Nephrol 2003 May;18(5):457-61. Epub 2003 Mar 18.

      ●● Enlace al texto completo (gratuito o de pago) 1007/s00467-003-1080-x

AUTORES / AUTHORS:  - Kim SS; Hicks J; Goldstein SL

INSTITUCIÓN / INSTITUTION:  - Baylor College of Medicine, Texas, USA.

RESUMEN / SUMMARY:  - Gross hematuria, graft pain, and rising serum creatinine are classic signs of acute rejection, obstruction, or bacterial pyelonephritis for patients with renal transplants. This presentation often prompts percutaneous renal allograft biopsy. If subsequent evaluation fails to show evidence of acute rejection, obstruction, or bacterial infection, viral etiologies should be considered. We report a 14-year-old Hispanic female with a living-related renal transplant who had gross hematuria, graft tenderness, and increased serum creatinine, but did not have evidence of acute rejection, obstruction, or bacterial pyelonephritis. To our knowledge, this is the first report of adenovirus pyelonephritis in a transplanted kidney of a pediatric patient, with isolation of adenovirus in the urine and in the allograft using immunocytochemical techniques.  N. Ref:: 26

 

----------------------------------------------------

[28]

TÍTULO / TITLE:  - Treatment of renal transplant ureterovesical anastomotic strictures using antegrade balloon dilation with or without holmium:YAG laser endoureterotomy.

REVISTA / JOURNAL:  - Urology 2003 Nov;62(5):831-4.

AUTORES / AUTHORS:  - Kristo B; Phelan MW; Gritsch HA; Schulam PG

INSTITUCIÓN / INSTITUTION:  - Department of Urology, University of California, Los Angeles, School of Medicine, Los Angeles, Medical Center, Los Angeles, California 90095, USA.

RESUMEN / SUMMARY:  - OBJECTIVES: To report our results after antegrade endoscopic treatment of ureteral stenosis with balloon dilation with or without holmium laser endoureterotomy. Ureteral stenosis is the most common long-term urologic complication of renal transplantation. METHODS: From July 2000 to October 2002, 9 renal transplant patients with ureteral obstruction diagnosed by an increase in serum creatinine and radiologic evidence presented for endoscopic treatment. All patients were treated with nephrostomy tube drainage followed by antegrade flexible nephroureteroscopy and balloon dilation of the stricture. Three patients required holmium laser endoureterotomy during the same procedure because of fluoroscopic and endoscopic evidence of persistent stricture. All patients were treated with ureteral stents and nephrostomy tubes postoperatively. The median follow-up was 24 months (range 6 to 32). RESULTS: The site of stenosis was at the ureterovesical anastomosis in all patients, and the mean stricture length was 0.28 cm. Two patients had previously undergone ureteroneocystostomy for prior ureteral stenosis. Six patients (66%) required only balloon dilation, and 3 patients (33%) also required holmium laser endoureterotomy. The median ureteral stent and nephrostomy tube duration was 40 and 62 days, respectively. The mean serum creatinine level was 2.3 mg/dL at presentation and 1.7 mg/dL at the last follow-up visit. After a median follow-up of 24 months, the ureteral patency and graft function rates were both 100%. No perioperative complications occurred. CONCLUSIONS: Balloon dilation with or without holmium laser endoureterotomy was successful and safe in this group of renal transplant patients with short ure